ES2146256T3 - Agentes de contraste que contienen perfluoro-1h,1h-neopentilo y metodo para usar el mismo. - Google Patents

Agentes de contraste que contienen perfluoro-1h,1h-neopentilo y metodo para usar el mismo.

Info

Publication number
ES2146256T3
ES2146256T3 ES94912759T ES94912759T ES2146256T3 ES 2146256 T3 ES2146256 T3 ES 2146256T3 ES 94912759 T ES94912759 T ES 94912759T ES 94912759 T ES94912759 T ES 94912759T ES 2146256 T3 ES2146256 T3 ES 2146256T3
Authority
ES
Spain
Prior art keywords
perfluoro
neopentilo
same
contrast agents
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94912759T
Other languages
English (en)
Inventor
Rolf Lohrmann
Ashwin Krishnan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Biosystems Inc
Original Assignee
Molecular Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Biosystems Inc filed Critical Molecular Biosystems Inc
Application granted granted Critical
Publication of ES2146256T3 publication Critical patent/ES2146256T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/10—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms
    • C07C17/14—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms in the side-chain of aromatic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/26—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/65—Halogen-containing esters of unsaturated acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

SE PROPORCIONAN COMPUESTOS ORGANICOS PARA LA FORMACION DE IMAGENES DE DIAGNOSTICO QUE CONTIENEN AL MENOS UN GRUPO ARILO QUE SE HA DERIVADO PARA CONTENER AL MENOS UNA UNIDAD PERFLUO-1H,1HNEOPENTILO.LOS GRUPOS PERFLUO-1H, 1H-NEOPENTILO PRODUCEN UNA UNICA RESONANCIA MAGNETICA PARA ASEGURAR UNA RELACION MAXIMA DE SEÑAL/RUIDO. UN COMPUESTO PRESENTADO ES 2-0-OLEOILGLICEROL 1,3BIS (7''-{3",5"-DI [2''''''2''''''-DI (TRIFLUOMETIL) 3'''''',3'''''',3''''''TRIFLUOPROPIL] FENIL}HEPTANOATO) .EN UNA FORMA PREFERIDA,SE PROPORCIONA UNA EMULSION DE LIPIDO COMO UN VEHICULO PORTADOR PARA SUMINISTRAR EL ANALOGO DERIVADO A UN RECEPTOR MAMIFERO.TAMBIEN SE PROPORCIONAN METODOS DE USO DE ESTOS COMPUESTOS EN MRI Y TOMOGRAFIA COMPUTERIZADA.
ES94912759T 1993-03-26 1994-03-09 Agentes de contraste que contienen perfluoro-1h,1h-neopentilo y metodo para usar el mismo. Expired - Lifetime ES2146256T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/037,279 US5401493A (en) 1993-03-26 1993-03-26 Perfluoro-1H,-1H-neopentyl containing contrast agents and method to use same

Publications (1)

Publication Number Publication Date
ES2146256T3 true ES2146256T3 (es) 2000-08-01

Family

ID=21893476

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94912759T Expired - Lifetime ES2146256T3 (es) 1993-03-26 1994-03-09 Agentes de contraste que contienen perfluoro-1h,1h-neopentilo y metodo para usar el mismo.

Country Status (8)

Country Link
US (1) US5401493A (es)
EP (1) EP0707624B1 (es)
JP (1) JPH08508729A (es)
AT (1) ATE192778T1 (es)
CA (1) CA2158279A1 (es)
DE (1) DE69424424T2 (es)
ES (1) ES2146256T3 (es)
WO (1) WO1994022368A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9205298A (es) * 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
CA2154590C (en) * 1993-01-25 2001-06-12 Steven C. Quay Phase shift colloids as ultrasound contrast agents
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
IL108416A (en) 1993-01-25 1998-10-30 Sonus Pharma Inc Phase shift colloids as ultrasound contrast agents
US5695740A (en) * 1993-05-12 1997-12-09 The Board Of Regents Of The University Of Nebraska Perfluorocarbon ultrasound contrast agent comprising microbubbles containing a filmogenic protein and a saccharide
US5701899A (en) * 1993-05-12 1997-12-30 The Board Of Regents Of The University Of Nebraska Perfluorobutane ultrasound contrast agent and methods for its manufacture and use
JPH0797340A (ja) * 1993-06-03 1995-04-11 Terumo Corp Ｍｒｉ造影剤組成物
WO1998053855A1 (en) * 1997-05-30 1998-12-03 Alliance Pharmaceutical Corp. Methods and apparatus for monitoring and quantifying the movement of fluid
US5622687A (en) * 1994-11-15 1997-04-22 Molecular Biosystems, Inc. Calixarene conjugates useful as MRI and CT diagnostic imaging agents
US5660815A (en) * 1995-04-28 1997-08-26 Molecular Biosystems, Inc. Water soluble fluorinated fatty acid sulfonate derivatives useful as magnetic resonance imaging agents
US5654452A (en) * 1995-06-07 1997-08-05 Molecular Biosystems, Inc. Lipophilic contrast agents for use in hepatocyte-selective oil-in-water emulsions
US5648098A (en) * 1995-10-17 1997-07-15 The Board Of Regents Of The University Of Nebraska Thrombolytic agents and methods of treatment for thrombosis
DE19603033A1 (de) 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
DE19608278A1 (de) * 1996-02-23 1997-08-28 Schering Ag Pharmazeutische Mittel enthaltend perfluoralkylhaltige Metallkomplexe, und ihre Verwendung in der Tumortherapie und interventioniellen Radiologie
US6180113B1 (en) 1996-02-23 2001-01-30 Schering Ag Pharmaceutical agents that contain perfluoroalkyl-containing metal complexes
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
US5849727A (en) * 1996-06-28 1998-12-15 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents
NL1004362C2 (nl) * 1996-10-25 1998-04-28 Stichting Vakraad Voor De Meub Inrichting voor het voor bewerking beweegbaar opstellen van een werkstuk.
DE19731300C1 (de) * 1997-07-11 1999-01-21 Schering Ag Perfluoralkylgruppenhaltige Trijodaromaten, Verfahren zu deren Herstellung und deren Verwendung als Kontrastmittel
IL147854A0 (en) * 1999-07-29 2002-08-14 Epix Medical Inc Multimeric compounds, contrast agents containing the same and diagnostic methods utilizing the same
US20030113267A1 (en) * 1999-12-29 2003-06-19 Knopp Michael V. Colon contrast enhanced imaging
TWI221406B (en) * 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
US20040126400A1 (en) * 2002-05-03 2004-07-01 Iversen Patrick L. Delivery of therapeutic compounds via microparticles or microbubbles
AR047692A1 (es) * 2003-07-10 2006-02-08 Epix Medical Inc Imagenes de blancos estacionarios
EP1828111A2 (en) * 2004-11-12 2007-09-05 Neurochem (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
WO2006096499A2 (en) * 2005-03-04 2006-09-14 Washington University Mr coronary angiography with a fluorinated nanoparticle contrast agent at 1.5 t
US7538236B2 (en) * 2006-01-04 2009-05-26 Suresh Narine Bioplastics, monomers thereof, and processes for the preparation thereof from agricultural feedstocks
DE102006049821A1 (de) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
AU2010246010A1 (en) * 2009-05-04 2011-11-17 Washington University PET radiotracers for imaging fatty acid metablolism and storage
CN114956951A (zh) * 2021-02-25 2022-08-30 中国科学院上海有机化学研究所 一种含氟叔碳中心的构建方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110474A (en) * 1977-08-26 1978-08-29 Suntech, Inc. Tetramethylpentane blood substitutes
US4187252A (en) * 1977-08-26 1980-02-05 Suntech, Inc. Tetramethylpentane blood substitutes
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4943595A (en) * 1981-09-08 1990-07-24 The Green Cross Corporation Perfluorochemicals and process for preparing the same
US4775522A (en) * 1983-03-04 1988-10-04 Children's Hospital Research Foundation, A Division Of Children's Hospital Medical Center NMR compositions for indirectly detecting a dissolved gas in an animal
US4558279A (en) * 1983-03-07 1985-12-10 University Of Cincinnati Methods for detecting and imaging a temperature of an object by nuclear magnetic resonance
GB8413772D0 (en) * 1984-05-30 1984-07-04 Nyegaard & Co As Chemical compounds
US4535184A (en) * 1984-06-08 1985-08-13 E. I. Du Pont De Nemours And Company Tris(disubstituted amino)sulfonium perfluorocarbanion salts
US4612185A (en) * 1984-10-15 1986-09-16 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
GB8801646D0 (en) * 1988-01-26 1988-02-24 Nycomed As Chemical compounds
NL8801937A (nl) * 1988-08-03 1990-03-01 Optische Ind De Oude Delft Nv Dosismeter voor ioniserende straling.
US5116599A (en) * 1989-07-31 1992-05-26 Johns Hopkins Univ. Perfluoro-t-butyl-containing compounds for use in fluorine-19 nmr and/or mri

Also Published As

Publication number Publication date
US5401493A (en) 1995-03-28
EP0707624A4 (en) 1996-02-29
EP0707624B1 (en) 2000-05-10
JPH08508729A (ja) 1996-09-17
EP0707624A1 (en) 1996-04-24
ATE192778T1 (de) 2000-05-15
DE69424424D1 (de) 2000-06-15
DE69424424T2 (de) 2000-09-21
WO1994022368A1 (en) 1994-10-13
CA2158279A1 (en) 1994-10-13

Similar Documents

Publication Publication Date Title
ES2146256T3 (es) Agentes de contraste que contienen perfluoro-1h,1h-neopentilo y metodo para usar el mismo.
WO1994022368B1 (en) Perfluoro-1h-1h-neopentyl containing contrast agents and method to use same
IS4833A (is) Lífefnafræðilega virkjuð skuggaefni til myndgreiningar
DK0802911T3 (da) Hydrofobe taxanderivater
ATE84414T1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus.
DK0588869T3 (da) Røntgenkontrastmiddel
DE69329304D1 (de) Enzymatische Verfahren zur Resolution von Enantiomeren-Mischungen nützlich wie Zwischenprodukte zur Herstellung von Taxanen
PL324342A1 (en) Complex compounds of a cascade polymer, method of obtaining them and pharmaceutic agents containing such compounds
DE59404433D1 (de) Meso-tetraphenylporphyrin-komplexverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
TR199900537T2 (xx) D�n��t�r�lm�� amino asitler, bunlar� i�eren farmas�tik preparatlar.
ES2056928T3 (es) Compuestos heterociclicos.
ATE201019T1 (de) 9-deoxotaxan verbindungen
ATE128138T1 (de) 13,17-propionsäure- und propionsäurederivat- substituierte porphyrin-komplexverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel.
AU2693195A (en) Emulsions of paramagnetic contrast agents for magnetic resonance imaging (mri), containing an organic chelator having an unsaturated aliphatic group
RU2002123877A (ru) Кахалалидные соединения
DE3867903D1 (de) Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle und diese mischkristalle enthaltende pharmazeutische mittel.
DE69314779D1 (de) Prozess zur herstellung von beta-phenylisoserin und analogen verbindungen
EP0268223A3 (de) Optisch aktive Gyrasehemmer, ihre Herstellung und Verwendung als Antibiotika
DE69627635D1 (de) Verfahren und vorrichtung zum umwickeln mit bandförmigem material
IT1291278B1 (it) Preparazione farmaceutica a base di nimesulide per uso topico
DE59108924D1 (de) Verfahren zur herstellung von mikronisierte wirkstoffe enthaltende halbfeste zubereitungen
DE69107616D1 (de) Phenolisches amin als antimelanoma- und depigmentierungsmittel.
KR930703013A (ko) 항당뇨병제로서 유용한 신규한 글루코하이드롤라제 억제제
WO1999002193A3 (de) Perfluoralkylgruppenhaltige trijodaromaten, verfahren zu deren herstellung und deren verwendung als kontrastmittel
AU2049995A (en) Tumor affinity peptide, and radioactive diagnostic agent and adioactive therapeutic agent containing the peptide

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 707624

Country of ref document: ES